ONO-2020

Ono Pharmaceutical Co. Ltd · Phase 2 active Small molecule

At a glance

Generic name	ONO-2020
Sponsor	Ono Pharmaceutical Co. Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease (PHASE2)
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia (PHASE2)
A Phase 1 Study of ONO-2020 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ONO-2020 CI brief — competitive landscape report
ONO-2020 updates RSS · CI watch RSS
Ono Pharmaceutical Co. Ltd portfolio CI